

Attachment E

**RESOLUTION OF THE STATE HEALTH BENEFITS PLAN
DESIGN COMMITTEE REGARDING COVERAGE FOR
TREATMENT FOR HEPATITIS C UNDER THE EMPLOYEE
AND RETIREE PRESCRIPTION DRUG BENEFIT PLANS**

WHEREAS, there are several drugs available to treat Hepatitis C with equal efficacy but the costs to the State Health Benefits Program ("SHBP") vary greatly;

THEREFORE, BE IT NOW RESOLVED that the SHBP PDC agrees that as soon as practical, but in no event later than October 1, 2015, (the "Effective Date") Viekira Pak will be the first-line medication (defined as the first treatment prescribed for a specific disease) for the treatment of Hepatitis C for genotype 1 patients. Sovaldi, Harvoni, and Olysio will be second-line medications (defined as the second treatment prescribed where (i) the first-line treatment doesn't work; (ii) the first-line treatment worked, but has since stopped working; and/or (iii) the first-line treatment has side effects that are not tolerated)

This change shall not apply to any member who has started therapy for Hepatitis C with one of the second-line medications prior to the Effective Date of this resolution.

The Committee Requests that the NJ SHBP and its PBM implement an appeals process consistent with all federal and state guidelines to review and determine if any prescribed second-tier medications originally rejected for coverage, are required because of medical necessity as determined under the existing rules of the Plan.